ClinicalTrials.gg
Not yet recruitingNCT07693933Updated Nov 6, 2026

Biodegradable Magnesium Screws for Unstable Ankle Fracture Surgery

An interventional study of RemeOs Magnesium-Based Biodegradable Screw in Ankle Fractures and Syndesmotic Injury, sponsored by Massachusetts General Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 6, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Ankle Fractures with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Ankle Fractures · United States.

Planned enrollment
32nd of 49
28 · median 55
Started
2027
the only one that year
No phase
37 of 60
13 open now
Primary completion
2029-02
later than 19 of 19 live
Registered
60th of 60
by date

Among the 60 studies in Ankle Fractures with a site in United States, this one is the 32nd largest by planned enrollment of the 49 interventional ones that give a count, is the only one that started in 2027, is one of 37 with no phase, reaches primary completion later than 19 of the 19 other live ones, and was the 60th registered.

Ankle Fractures

203 studies on the registry are indexed under Ankle Fractures; 45 are open to participants now.

Browse Ankle Fractures studies →

Open to participants now

16 of the 60 studies in Ankle Fractures with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Ankle Fractures studies recruiting now, 14 (45%) set no upper age limit and 12 (39%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Ankle Fractures with a site in United States, or all of them as a file.
02

Study summary

Ankle fractures are among the most common injuries that need surgery. When the broken bones make the ankle unstable, surgeons usually fix them with metal screws and plates. Metal hardware holds the bones in place well, but it can cause irritation, can loosen or break, and often has to be removed in a second surgery later.

This study looks at a different kind of screw called the RemeOs magnesium-based screw. It is made from a magnesium alloy and is designed to slowly dissolve and be absorbed by the body over about two to three years after it has done its job of holding the bone together. Because it dissolves on its own, patients may not need a second surgery to remove the hardware. These screws are authorized by the U.S. Food and Drug Administration (FDA) for use in medial malleolus ankle fractures. In this study, they are being used as an off-label indication.

The purpose of this study is to learn how well these magnesium screws work and how safe they are when used to repair unstable ankle fractures. The study will enroll at least 25 adults (ages 18 to 80) who have an unstable ankle fracture that needs surgery. All participants will have their fracture repaired with RemeOs screws as part of their normal surgical care.

After surgery, participants will be followed for 12 months. They will return for check-ups at about 6 weeks, 3 months, 6 months, and 12 months. At these visits, the study team will examine the ankle, take X-rays to see how the bone is healing and how the screws are dissolving, ask about any complications, and have participants fill out questionnaires about their ankle function and pain.

The main thing the study measures is ankle function at 12 months, scored using a standard ankle questionnaire (the Olerud-Molander Ankle Score). The study also tracks pain, healing on X-rays, how the screws break down over time, and any complications such as infection, loss of fixation, non-healing, or the need for additional surgery.

The surgery, X-rays, and follow-up visits in this study are the same care patients would receive whether or not they take part. The only research-specific parts are giving consent and filling out the study questionnaires. Taking part is voluntary and does not change the care a patient receives.

Read the detailed description

Background: A substantial proportion of operatively treated lower-extremity injuries are ankle fractures, including unimalleolar, bimalleolar, bimalleolar-equivalent, and trimalleolar patterns, often with associated distal tibiofibular syndesmotic instability. Conventional metallic fixation provides reliable initial stability but carries well-recognized drawbacks, including hardware irritation, implant breakage or loosening, and the frequent need for secondary removal procedures-particularly for syndesmotic screws. Magnesium-based biodegradable implants are designed to provide sufficient mechanical stability during fracture healing while gradually degrading, thereby eliminating routine hardware removal. RemeOs magnesium-based screws (Bioretec), composed of a magnesium-calcium-zinc alloy, medial malleolus ankle fractures and are absorbed over approximately 2 to 3 years.

Design: This is a prospective, single-arm, interventional, post-market clinical follow-up study. A minimum of 25 patients (planned enrollment of 28 to allow for attrition) will be enrolled at participating Mass General Brigham sites. Fellowship-trained orthopaedic foot and ankle surgeons will perform all procedures.

Intervention: All participants will undergo open reduction and internal fixation (ORIF) of their ankle fracture using RemeOs magnesium-based biodegradable screws for fracture fixation and/or syndesmotic stabilization, in accordance with the device Instructions for Use. RemeOs screw types (Screw LAG, Screw COM, Screw FT, and Screw LAG Solid) may be used at the surgeon's discretion. Fixation of additional fracture components may be supplemented with plates, K-wires, or non-resorbable screws as clinically indicated.

Assessments: Participants are evaluated preoperatively (baseline characteristics, radiographs, and patient-reported outcomes) and postoperatively at 6 weeks, 3 months, 6 months, and 12 months, with an optional 9-month visit if delayed healing or complications are suspected. Each follow-up includes clinical examination, radiographic assessment of healing and screw biodegradation, complication assessment, and patient-reported outcomes.

Primary outcome: Functional recovery measured by the Olerud-Molander Ankle Score (OMAS) at 12 months.

Secondary outcomes: OMAS at 3 and 6 months; radiographic fracture healing and alignment; radiographic evaluation of RemeOs screw biodegradation; complication rates (loss of fixation, infection, non-union, revision surgery); pain intensity (Visual Analog Scale); and PROMIS Physical Function and Pain Interference.

Statistical analysis: Longitudinal OMAS changes will be analyzed using a linear mixed-effects model with time as a fixed effect and subject as a random effect. Secondary outcomes will be summarized descriptively; continuous variables compared with paired t-tests or Mann-Whitney U tests as appropriate; time to revision evaluated by Kaplan-Meier analysis where applicable. A p-value \< 0.05 is considered significant.

All clinical procedures (surgery, imaging, follow-up) are standard care delivered regardless of study participation; the only research-specific procedures are informed consent and completion of patient-reported outcome measures.

03

Conditions studied

  • Ankle Fractures
  • Syndesmotic Injury

Keywords

  • Magnesium-based screw
  • Biodegradable implant
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80 years
  • Unstable closed ankle fracture requiring surgical fixation, including unimalleolar, bimalleolar, bimalleolar-equivalent, or trimalleolar fractures
  • Fractures may be with or without syndesmotic instability
  • Willingness to follow postoperative visits and rehabilitation protocols
  • Ability to complete patient-reported outcome measures (PROMs)

Exclusion criteria

Exclusion Criteria:

  • (BMI) > 40
  • Open fractures
  • Pathologic fractures
  • Active infection at the surgical site
  • Known allergy or to magnesium or implant components
  • Severe peripheral vascular disease
  • Uncontrolled diabetes mellitus
  • Prior ankle surgery on the affected limb
  • Concomitant osteochondral lesions requiring treatment
  • Neuromuscular disorders affecting the lower extremity
  • Worker's compensation cases
  • Pregnancy
  • Non-adherence concerns or inability to comply with follow-up requirements
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    RemeOs Magnesium Screw Fixation

    All participants undergo open reduction and internal fixation (ORIF) of their unstable ankle fracture using RemeOs magnesium-based biodegradable screws for fracture fixation and/or syndesmotic stabilization, in accordance with the device Instructions for Use. Screw type is selected at the surgeon's discretion. Additional fracture components may be supplemented with plates, K-wires, or non-resorbable screws as clinically indicated. Participants are followed for 12 months postoperatively.

    Device: RemeOs Magnesium-Based Biodegradable Screw

Interventions

  • DeviceRemeOs Magnesium-Based Biodegradable Screw

    ORIF performed using RemeOs magnesium-alloy biodegradable screws (Screw LAG, Screw COM, Screw FT, and/or Screw LAG Solid) for fixation of any malleolus and/or for syndesmotic fixation where indicated, per the device Instructions for Use. The screws provide mechanical stability during healing and gradually biodegrade over approximately 2-3 years, eliminating the need for routine hardware removal.

06

What researchers measure

Primary outcomes

  1. Olerud-Molander Ankle Score (OMAS)

    Functional recovery assessed by the Olerud-Molander Ankle Score, a patient-reported instrument scored 0 to 100, where 0 indicates totally impaired and 100 indicates no impairment. Higher scores indicate better ankle function.

    Time frame: 12 months

Secondary outcomes

  1. Radiographic Fracture Healing and Alignment

    Radiographic assessment of fracture union and maintenance of anatomic alignment of the ankle mortise on serial postoperative radiographs.

    Time frame: 6 weeks, 3 months, 6 months, and 12 months postoperatively

  2. Radiographic RemeOs Screw Biodegradation

    Radiographic evaluation of the biodegradation behavior of the RemeOs magnesium-based screws over time, including gas formation and implant resorption.

    Time frame: 3 months, 6 months, and 12 months postoperatively

  3. Complication Rate

    Proportion of participants experiencing complications, including loss of fixation, infection, non-union, and revision surgery.

    Time frame: 12 months

  4. Pain Intensity

    Pain intensity measured on a Visual Analog Scale ranging from 0 (no pain) to 10 (worst imaginable pain); lower scores indicate less pain.

    Time frame: Baseline, 6 weeks, 3 months, 6 months, and 12 months postoperatively

  5. PROMIS

    ROMIS Physical Function and PROMIS Pain Interference. Both are reported as Patient-Reported Outcomes Measurement Information System (PROMIS) T-scores standardized to the US general population (mean 50, SD 10, minimum 0, maximum 100). For Physical Function, higher scores indicate a better outcome. For Pain Interference, higher scores indicate a worse outcome.

    Time frame: Baseline, 6 weeks, 3 months, 6 months, and 12 months postoperatively

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will be stored within Mass General Brigham and accessed only by IRB-approved study staff. Per the study protocol, data will not be shared outside the institution, and no biological specimens are collected.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2027; primary completion for Feb 2029, 22 months later.

Of 69 non-industry interventional studies with no phase under Ankle Fractures, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's planned 22 months is below that.

Counting every sponsor, half of 72 studies reached it within 45 months; a quarter within 23 and three quarters within 61.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Apr 2027, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2026
First posted
Jul 9, 2026
StartEst.
Apr 2027was Aug 2026
Primary completionEst.
Feb 2029
CompletionEst.
Mar 2029
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2026→Apr 2027
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Start date Aug 2026→Apr 2027
    + 3 other changes: verification date, registry dates and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07693933
Collaborators
Bioretec Ltd.
Responsible party
Soheil Ashkani Esfahani (Director of Foot & Ankle Research and Innovation Lab (FARIL), Massachusetts General Hospital) — Principal investigator
First posted
Jul 9, 2026
Start date
Apr 2027 (estimated)
Primary completion
Feb 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

Mani Eftekhari, BS
Contact
meftekhari@mgh.harvard.edu
15108506056

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion